GRAIL, Inc. Common Stock — informes financieros trimestrales (NASDAQ:GRAL)

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Trimestre Año

Market Capitalization 2.1363 B
Employee 910
Founded 2015
CEO N/A
Website www.grail.com
Headquarter Delaware, United States
FIGI BBG01N6CGW43
Industry Diagnóstico y pruebas

Ingresos totales

Beneficio neto

Beneficio básico por acción

Deuda total

Flujo de caja libre

Efectivo y equivalentes

2.14 B Capitalización de mercado

Ratio precio/beneficio

-7.7

Relación precio/flujo de caja

21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.